Agenus Reports 72% Pathologic Complete Response Rate with BOT+BAL in Phase 2 NEOASIS Trial at ESMO 2026

Agenus reported Phase 2 NEOASIS trial results for dMMR colon cancer patients, showing 72% achieved a pathologic complete response and 83% a major pathologic response after six weeks of BOT+BAL treatment. The trial met its primary endpoint. Investigators plan to explore organ preservation in rectal cancer patients.

Original reporting
Published Oct 25, 2026, 4:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Agenus Reports 72% Pathologic Complete Response Rate with BOT+BAL in Phase 2 NEOASIS Trial at ESMO 2026 — source image
Decision brief

The 30-second read

$AGENBullishMed
01

Why it matters

The 72% pCR rate is a compelling early signal that could accelerate the program and attract partnership interest.

02

Market read

First report of strong Phase 2 data for a niche oncology indication; likely to move Agenus stock and influence peer biotech valuations.

03

What to watch

Regulatory pathway and reimbursement considerations could temper upside despite strong data.

Relevance 8/10Novelty 8/10Timing: today

Background

Agenus (NASDAQ: AGEN) is a biotech developing immunotherapy agents. The NEOASIS trial evaluates botensilimab plus balstilimab in mismatch repair‑deficient colon cancer.

Company-level read

Ticker impact

$AGENBullishHigh confidence
Context

Agenus announced Phase 2 data showing 72% pathologic complete response in dMMR colon cancer patients.

Expected impact

upward pressure as investors price in the high response rate.

Evidence & confidence

Phase 2 data with 72% pCR is unusually strong for a biotech and may accelerate development timelines.

Market effects

May lift other dMMR-focused immunotherapy stocks as the data validates the approach.

Limited to US biotech sector; no broader regional effect.

Modest global relevance, primarily for investors tracking oncology pipelines.

Counterpoint

Skeptics may note the small sample size (18 patients) and wait for larger trials before acting.

Key entities

  • Agenus

    Biotech firm developing immunotherapy.

  • botensilimab (BOT)

    Anti‑PD‑1 antibody.

  • balstilimab (BAL)

    Anti‑PD‑L1 antibody.

Related articles

$AGENMedAI 8/10

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

$AGENMedAI 8/10

Agenus advances Phase 3 colon cancer trial, posts Q3 profit

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.